Showing results (3651-3660 of 5,702) with videos related to
Sort By:
Pageof 571
The Oncologist|September 10, 2009
The chronology of distress, anxiety, and depression in older prostate cancer patientsChristian J Nelson, Mark I Weinberger, Eliana Balk, et al.The Oncologist|September 4, 2009
Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinomaTakanori Hama, Yuki Yuza, Yoshimichi Saito, et al.The Oncologist|August 18, 2009
Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literatureAndrew J Armstrong, Phillip G FebboThe Oncologist|November 11, 2008
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLCRoy S Herbst, Alan SandlerThe Oncologist|August 13, 2008
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapyCherry L Estilo, Catherine H Van Poznak, Tijaana Wiliams, et al.The Oncologist|August 13, 2008
Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology settingTrevor McKibbin, Christopher R Frei, Rebecca E Greene, et al.The Oncologist|August 13, 2008
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumorsLissandra Dal Lago, Véronique D'Hondt, Ahmad AwadaThe Oncologist|September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture, Shenhong Wu, Caroline Robert, et al.The Oncologist|September 10, 2008
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapyXuhui Zhou, Weiguo Hu, Xuebin QinThe Oncologist|September 24, 2005
Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderlyTarun Wasil, Stuart M LichtmanPageof 571